Form 483

Haw Par Healthcare Ltd. Form 483, 2024-09-27

FDA issued a Form 483 to Haw Par Healthcare Ltd. on 2024-09-27 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

Haw Par Healthcare Ltd. · Singapore, Singapore · Issued September 27, 2024

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

27 Sep 2024
21 CFR 211.111

Establishment of time limitations

Cited by Tamil Arasu, Samantha E Cleek

27 Sep 2024
21 CFR 211.130(c)

Lot or control number assigned

Cited by Tamil Arasu, Samantha E Cleek

27 Sep 2024
21 CFR 211.165(b)

Microbiological testing

Cited by Tamil Arasu, Samantha E Cleek

27 Sep 2024
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Tamil Arasu, Samantha E Cleek

27 Sep 2024
21 CFR 211.198(b)(3)

Reason for Not Conducting Complaint Investigation

Cited by Tamil Arasu, Samantha E Cleek

Inspected site

HPHaw Par Healthcare Ltd.Singapore, Singapore

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.111Cited across public-safe Form 483 observations1x
21 CFR 211.130(c)Cited across public-safe Form 483 observations1x
21 CFR 211.165(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.198(b)(3)Cited across public-safe Form 483 observations1x
21 CFR 211.80(a)Cited across public-safe Form 483 observations1x
21 CFR 211.80(d)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere